About this event:

Date: July 31, 2025

Time: 11 am ET | 8 am PT |
5 pm CEST

Duration: 30 minutes

ADC development is inherently complex due to the hybrid nature of the molecule, which integrates three distinct components: a monoclonal antibody, a cytotoxic payload, and a chemical linker that must maintain stability in circulation while releasing the drug at the tumor site. Each of these elements introduces unique technical challenges that must be addressed in a coordinated, cross-disciplinary manner.

Samsung Biologics supports a full suite of in-house analytical capabilities specifically designed for ADCs. Key methods include accurate measurement of the drug-antibody ratio, which is critical for understanding product potency and consistency. Free drug quantification ensures that unbound payloads are kept within safe and acceptable limits, helping to reduce toxicity risk. Residual solvent analysis confirms that manufacturing processes meet global regulatory standards for purity and safety.

Recognizing that ADCs span a range of chemistries and structural complexities, from various types of conjugation technology and bioconjugates, Samsung Biologics tailors its analytical testing scope to the specific needs of each molecule and clinical development plan.

In this webinar, you will learn how a client-centric, technically rigorous approach to analytical activities for ADCs ensures that analytical strategies are precisely aligned with each program’s therapeutic goals, conjugation modality, and regulatory requirements.

Key Takeaways:

• Overcome technical complexity with platform capabilities
• Leverage comprehensive analytical capabilities and flexible execution
• Adopt a strategic approach to analytical method development.